Vaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting ...

Stock futures edged lower on Monday due to trade war concerns and the upcoming 25% levy on non-US cars. President Trump has ...

Vaxcyte plunges 56% even though its VAX-24 pneumonia vaccine shows positive phase two results in infants. Read more here.

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious ...

At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At ...

Vaxcyte (PCVX) shared topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, ...

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect ...